{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T20:04:55Z","timestamp":1720382695399},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.leukres.2016.11.012","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T16:16:11Z","timestamp":1480090571000},"page":"35-38","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50%"],"prefix":"10.1016","volume":"53","author":[{"given":"Tomoyuki","family":"Uchida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.leukres.2016.11.012_bib0005","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.leukres.2016.11.012_bib0010","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2016.11.012_bib0015","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3324\/haematol.2011.043687","article-title":"Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells","volume":"96","author":"Bacher","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2016.11.012_bib0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.leukres.2016.11.012_bib0025","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.11.012_bib0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-8722-6-32","article-title":"Azacitidine in patients with WHO-defined AML\u2014results of 155 patients from the austrian azacitidine registry of the AGMT-Study group","volume":"6","author":"Pleyer","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2016.11.012_bib0035","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00277-012-1603-2","article-title":"Erythroleukemia showing early erythroid and cytogenetic responses to azacitidine therapy","volume":"92","author":"Hangai","year":"2013","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2016.11.012_bib0040","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0609.2012.01816.x","article-title":"Durable complete remission after azacitidine treatment in a patient with erythroleukaemia","volume":"89","author":"Hansen","year":"2012","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2016.11.012_bib0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lrr.2013.04.001","article-title":"Treatment of acute erythroleukemia with Azacitidine: a case series","volume":"2","author":"Pierdomenico","year":"2016","journal-title":"Leukemia Res. Rep."},{"issue":"9","key":"10.1016\/j.leukres.2016.11.012_bib0050","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/blood-2008-10-182782","article-title":"Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system","volume":"113","author":"Weinberg","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2016.11.012_bib0055","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1038\/leu.2009.181","article-title":"Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution","volume":"23","author":"Santos","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2016.11.012_bib0060","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0021-9258(19)68144-5","article-title":"Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine","volume":"257","author":"Creusot","year":"1982","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.leukres.2016.11.012_bib0065","first-page":"1613","article-title":"Human leukemic K562 cells: differential effects of 5-azacytidine on DNA methylation of epsilon-, gamma-globin and 7SL RNA genes","volume":"60","author":"del Senno","year":"1984","journal-title":"Bollettino della Societa italiana di biologia sperimentale"},{"issue":"5","key":"10.1016\/j.leukres.2016.11.012_bib0070","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2010.31.0854","article-title":"Hypomethylating agents and other novel strategies in myelodysplastic syndromes","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2016.11.012_bib0075","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3109\/10428194.2015.1079318","article-title":"Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response","volume":"57","author":"Peng","year":"2016","journal-title":"Leukemia Lymphoma"},{"issue":"10","key":"10.1016\/j.leukres.2016.11.012_bib0080","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2009-09-243964","article-title":"Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification","volume":"115","author":"Hasserjian","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2016.11.012_bib0085","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/modpathol.2008.142","article-title":"Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification","volume":"21","author":"Wang","year":"2008","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.leukres.2016.11.012_bib0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.66.9705","article-title":"Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes","author":"Arenillas","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.11.012_bib0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.leukres.2016.05.006","article-title":"Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: is there biologic significance? (How should blasts be counted?)","volume":"47","author":"Bennett","year":"2016","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.leukres.2016.11.012_bib0100","first-page":"289","article-title":"Acute myeloid leukaemia and myelodysplastic syndromes with 50% or greater erythroblasts: a diagnostic conundrum","volume":"47","author":"Wong","year":"2016","journal-title":"Pathology (Phila.)"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616302582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T19:36:03Z","timestamp":1657827363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616302582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":20,"alternative-id":["S0145212616302582"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.11.012","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50%","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}